Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Kartos Therapeutics, Inc.)"
Count: 15
Selected: 0
| NCT ID | Title |
|---|
| NCT04640532 | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | ||
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | ||
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | ||
| NCT04878003 | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | ||
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | ||
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | ||
| NCT04485260 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | ||
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | ||
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | ||
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | ||
| NCT03662126 | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | ||
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | ||
| NCT02016729 | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | ||
| NCT01723020 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | ||
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia |
